| [July 29, 2011] |
 |
Research and Markets: Aids - Related Lymphoma - Pipeline Review, Q3 2011 Is Built Using Data and Information Sourced from Proprietary Databases
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/c739eb/aids_related_lym)
has announced the addition of Global Markets Direct's new report "Aids
- Related Lymphoma - Pipeline Review, Q3 2011" to their offering.
Global Markets Direct's, 'Aids
- Related Lymphoma - Pipeline Review, Q3 2011', provides an overview
of the Aids - Related Lymphoma therapeutic pipeline. This report
provides information on the therapeutic development for Aids - Related
Lymphoma, complete with latest updates, and special features on
late-stage and discontinued projects. It also reviews key players
involved in the therapeutic deelopment for Aids - Related Lymphoma. 'Aids
- Related Lymphoma - Pipeline Review, Q3 2011' is built using data
and information sourced from Global Markets Direct's proprietary
databases, Company/University websites, SEC (News - Alert) filings, investor
presentations and featured press releases from company/university sites
and industry-specific third party sources, put together by Global
Markets Direct's team.
Scope
-
A snapshot of the global therapeutic scenario for Aids - Related
Lymphoma.
-
A review of the Aids - Related Lymphoma products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources.
-
Coverage of products based on various stages of development ranging
from discovery till registration stages.
-
A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.
-
Coverage of the Aids - Related Lymphoma pipeline on the basis of
therapeutic class, route of administration and molecule type.
-
Profiles of late-stage pipeline products featuring sections on product
description, mechanism of action and research & development progress.
-
Key discontinued pipeline projects.
-
Latest news and deals relating to the products.
Reasons to buy
-
Identify and understand important and diverse types of therapeutics
under development for Aids - Related Lymphoma.
-
Identify emerging players with potentially strong product portfolio
and design effective counter-strategies to gain competitive advantage.
-
Plan mergers and acquisitions effectively by identifying players with
the most promising pipeline.
-
Devise corrective measures for pipeline projects by understanding Aids
- Related Lymphoma pipeline depth and focus of Aids - Related Lymphoma
therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline.
For more information visit http://www.researchandmarkets.com/research/c739eb/aids_related_lym

[ Back To TMCnet.com's Homepage ]
|